- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Medicus Pharma recruits first patient in cancer patch trial | 2 | PMLiVE | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT in Patients with Gorlin Syndrome | 89 | GlobeNewswire (Europe) | PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 22.10. | Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 205 | ACCESS Newswire | CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the... ► Artikel lesen | |
| 17.10. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10. | The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets | 229 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / October 14, 2025 / Most biotech stories collapse on a single product failure. Medicus Pharma Ltd (NASDAQ:MDCX) built three distinct shots at blockbuster markets.The NASDAQ-listed... ► Artikel lesen | |
| 13.10. | Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 | 212 | ACCESS Newswire | EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX)... ► Artikel lesen | |
| 07.10. | Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE | 215 | ACCESS Newswire | EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSIONThe Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7... ► Artikel lesen | |
| 29.09. | Medicus Pharma Ltd. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.09. | Medicus Pharma gets FDA nod for 505(b)(2) pathway in skin cancer treatment | 1 | Investing.com | ||
| 29.09. | Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration Type C Meeting Supporting the Development of Skinject | 192 | ACCESS Newswire | The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA)... ► Artikel lesen | |
| 24.09. | Medicus Pharma Ltd. To Present at Brookline Capital Markets | 254 | ACCESS Newswire | The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix... ► Artikel lesen | |
| 18.09. | Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing | 272 | ACCESS Newswire | The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV... ► Artikel lesen | |
| 12.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | Medicus Pharma Ltd. Provides Update on United Arab Emirates SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 296 | ACCESS Newswire | CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"... ► Artikel lesen | |
| 02.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Medicus Pharma Ltd. Completes Acquisition of Antev Limited | 435 | Newsfile | Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma... ► Artikel lesen | |
| 22.08. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Medicus Pharma Ltd. reports Q2 results | 1 | Seeking Alpha | ||
| 21.08. | Medicus Pharma erzielt Fortschritte bei Hautkrebsmittel vor FDA-Gespräch | 3 | Investing.com Deutsch | ||
| 21.08. | Medicus Pharma advances skin cancer treatment as FDA meeting approaches | 1 | Investing.com |
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,290 | -0,19 % | Kreise: Novo Nordisk will Pfizer Biotech-Unternehmen Metsera wegschnappen | LONDON (dpa-AFX) - Der Pharmakonzern Novo Nordisk will sein Geschäft mit Abnehmmedikamenten laut Insidern durch die Übernahme der Biotechfirma Metsera schützen. Denn damit würden die Dänen Metsera... ► Artikel lesen | |
| GILEAD SCIENCES | 103,02 | -0,71 % | Chance für Anleger?: Gilead gibt Zahlen bekannt - Boost für Gewinnprognose? | Gilead gab steigende Umsätze mit HIV-Medikamentenverkäufen bekannt. Das Unternehmen erwartet in Zukunft Großes.Das Unternehmen meldete am Donnerstag einen Anstieg der HIV-Medikamentenverkäufe um 4 Prozent... ► Artikel lesen | |
| ELI LILLY | 742,80 | +2,03 % | Live-Event: Blickwechsel Stoffwechsel von Lilly in Kooperation mit der Universitätsmedizin Mainz / Neue Impulse für die Adipositasversorgung von morgen: Interdisziplinäre Lösungen, starker Dialog | Bad Homburg (ots) - Die Veranstaltungsreihe "Blickwechsel Stoffwechsel" hat mit der "Zukunftswerkstatt Adipositas" in Mainz eine starke neue Wegmarke für die Adipositasversorgung gesetzt. Initiiert... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 369,85 | +0,27 % | H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX) | ||
| EYEPOINT PHARMACEUTICALS | 10,465 | -7,10 % | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| ASTRIA THERAPEUTICS | 10,800 | -1,82 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| OPKO HEALTH | 1,230 | +2,40 % | OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results | MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 164,00 | -1,20 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 119,40 | 0,00 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 | DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5... ► Artikel lesen | |
| UNITED THERAPEUTICS | 384,20 | -0,65 % | United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark | ||
| ROYALTY PHARMA | 32,500 | -0,40 % | How Royalty Pharma Prints Cash Without Biotech's Biggest Risks | ||
| CATALYST PHARMACEUTICALS | 18,420 | +0,16 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 54,14 | -0,77 % | AKTIONÄR-Tipp BridgeBio erneut mit Kurssprung - Aktie bereits 100 Prozent im Plus | Bei der Aktie des US-Biotech-Unternehmens BridgeBio geht es weiter steil aufwärts. Bereits in den vergangenen Monaten hatte sich das Papier nach der Empfehlung als Jahrestipp in Ausgabe 52/2024 - 01/2025... ► Artikel lesen | |
| TG THERAPEUTICS | 30,915 | +2,15 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 16,400 | 0,00 % | Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc | DJ Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
27-Oct-2025 / 13:34 GMT/BST
... ► Artikel lesen |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -1,43 % bei einem Aktienkurs von 2,415 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.